Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free RDY Stock Alerts

Dr. Reddy's Laboratories (RDY) Competitors

Dr. Reddy's Laboratories logo
$12.35 +0.16 (+1.33%)
As of 10:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

RDY vs. ONC, RPRX, ZTS, VTRS, and JAZZ

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? Dr. Reddy's Laboratories's main competitors and comparable companies include BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), and Jazz Pharmaceuticals (JAZZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Dr. Reddy's Laboratories (NYSE:RDY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 1 mentions for BeOne Medicines. Dr. Reddy's Laboratories' average media sentiment score of 0.44 beat BeOne Medicines' score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BeOne Medicines
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$331.19B0.03$456M$0.4427.71
BeOne Medicines$6.13B6.28$286.93M$5.6861.77

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BeOne Medicines has a consensus price target of $402.71, suggesting a potential upside of 14.79%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
BeOne Medicines
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
3 Strong Buy rating(s)
3.00

BeOne Medicines has a net margin of 10.70% compared to Dr. Reddy's Laboratories' net margin of 10.15%. BeOne Medicines' return on equity of 14.23% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
BeOne Medicines 10.70%14.23%7.82%

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Royalty Pharma presently has a consensus target price of $61.29, suggesting a potential upside of 4.92%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Royalty Pharma's return on equity of 30.01% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma32.14% 30.01% 14.91%
Dr. Reddy's Laboratories 10.15%9.49%6.32%

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Royalty Pharma had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Royalty Pharma and 4 mentions for Dr. Reddy's Laboratories. Royalty Pharma's average media sentiment score of 0.98 beat Dr. Reddy's Laboratories' score of 0.44 indicating that Royalty Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Royalty Pharma has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.54B13.24$770.95M$1.4540.28
Dr. Reddy's Laboratories$331.19B0.03$456M$0.4427.71

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 17 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Zoetis?

Dr. Reddy's Laboratories (NYSE:RDY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Zoetis has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Zoetis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$331.19B0.03$456M$0.4427.71
Zoetis$9.53B3.10$2.67B$6.0711.78

In the previous week, Zoetis had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Zoetis and 4 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.44 beat Zoetis' score of 0.16 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zoetis
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Zoetis' return on equity of 74.89% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Zoetis 27.49%74.89%18.59%

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 3.0%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Zoetis pays out 34.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zoetis has a consensus target price of $101.08, indicating a potential upside of 41.30%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Zoetis
2 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.32

Summary

Zoetis beats Dr. Reddy's Laboratories on 14 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Viatris?

Dr. Reddy's Laboratories (NYSE:RDY) and Viatris (NASDAQ:VTRS) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Dr. Reddy's Laboratories has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$331.19B0.03$456M$0.4427.71
Viatris$14.74B1.32-$3.51B-$0.36N/A

In the previous week, Viatris had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Viatris and 4 mentions for Dr. Reddy's Laboratories. Viatris' average media sentiment score of 0.76 beat Dr. Reddy's Laboratories' score of 0.44 indicating that Viatris is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Viatris
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Viatris has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Viatris pays out -133.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Viatris -2.79%20.02%8.02%

Viatris has a consensus target price of $18.71, indicating a potential upside of 10.41%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Viatris
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

Viatris beats Dr. Reddy's Laboratories on 12 of the 18 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Jazz Pharmaceuticals?

Dr. Reddy's Laboratories (NYSE:RDY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Jazz Pharmaceuticals' return on equity of 33.97% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Jazz Pharmaceuticals 20.45%33.97%13.02%

Dr. Reddy's Laboratories has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$331.19B0.03$456M$0.4427.71
Jazz Pharmaceuticals$4.27B3.66-$356.15M$14.5016.60

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.44 beat Jazz Pharmaceuticals' score of 0.44 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Jazz Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jazz Pharmaceuticals has a consensus target price of $286.72, suggesting a potential upside of 19.10%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Jazz Pharmaceuticals beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

Export
MetricDr. Reddy's LaboratoriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$10.17B$12.42B$7.22B$23.03B
Dividend Yield0.53%2.64%2.57%3.62%
P/E Ratio27.71797.26275.4928.21
Price / Sales0.03791.59689.4190.54
Price / Cash14.3915.0828.1319.32
Price / Book2.5110.5010.604.70
Net Income$456M$2.82B$3.49B$1.07B
7 Day Performance2.42%-0.24%-0.27%-1.26%
1 Month Performance0.02%-0.86%-2.70%-4.29%
1 Year Performance-17.95%3.94%18.15%8.41%

Dr. Reddy's Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDY
Dr. Reddy's Laboratories
1.6692 of 5 stars		$12.35
+1.3%		N/A-17.9%$10.31B$331.19B28.0827,527
ONC
BeOne Medicines
3.0548 of 5 stars		$353.37
+1.5%		$402.71
+14.0%		+4.9%$38.80B$5.34B62.2212,000
RPRX
Royalty Pharma
3.8179 of 5 stars		$58.66
+0.3%		$61.29
+4.5%		+61.2%$33.71B$2.38B40.43100
ZTS
Zoetis
4.5548 of 5 stars		$72.24
-1.0%		$101.08
+39.9%		-50.9%$29.85B$9.47B11.9014,500
VTRS
Viatris
2.8265 of 5 stars		$17.18
+0.9%		$18.71
+9.0%		+71.2%$19.70B$14.30BN/A30,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 9/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel